Can Japanese T-cell immunotherapy prevent recurrence and metastasis of gastric cancer?

According to Hong Kong An Health Report, Japanese T cell immunotherapy is a brand-new method to prevent cancer recurrence. Starting from the origin of human immunity, it kills tumor cells with human immune cells. T cell immunotherapy in Japan is to transfuse cultured immune cells with high tumor killing activity into patients. These immune cells can not only kill tumor cells persistently and effectively in the body, but also improve the immune function of patients, search and kill tumor cells comprehensively, so that tumor cells hidden in blood, lymph and other corners of the human body have nowhere to hide, thus preventing the recurrence of gastric cancer and prolonging the survival time of patients.

Japan's T-cell immunotherapy has world-leading extraction technology and excellent laboratory equipment, which makes cell extraction and separation more accurate and ensures the purity of cells. Moreover, the whole culture process is carried out under aseptic management according to GMP (good manufacturing practice) standard, and the proliferated and activated immune cells can be cultivated, and the cell survival rate can be guaranteed at 97% when transfused to patients, thus achieving the expected therapeutic effect.

The difference of T cell immunotherapy in Japan is that it transfers the therapeutic target from tumor cells to immune cells, and treats tumors by enhancing patients' own anti-tumor immunity. Compared with traditional treatment, it has the advantages of accurate killing, lasting curative effect and high degree of personalization. In addition, the body's immune system has the characteristics of immune memory, so T cell immunotherapy can help patients form memory immunity, which has significant advantages in preventing tumor recurrence and metastasis.